文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.

作者信息

Reck Martin, Rabe Klaus F

机构信息

From LungenClinic Grosshansdorf and Airway Research Center North, Grosshansdorf (M.R., K.F.R.), the German Center for Lung Research, Giessen (M.R., K.F.R.), University of Lübeck, Lübeck (M.R.), and Christian Albrechts University Kiel, Kiel (K.F.R.) - all in Germany.

出版信息

N Engl J Med. 2017 Aug 31;377(9):849-861. doi: 10.1056/NEJMra1703413.

DOI:10.1056/NEJMra1703413
PMID:28854088
Abstract
摘要

相似文献

[1]
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.

N Engl J Med. 2017-8-31

[2]
Endobronchial ultrasonography (EBUS)--its role in staging of non-small cell lung cancer and who should do it?

J Thorac Cardiovasc Surg. 2012-9

[3]
EGFR mutations in non-small-cell lung cancer.

Lancet Oncol. 2010-5

[4]
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

J Oncol Pract. 2017-12

[5]
The cellular origins of drug resistance in cancer.

Nat Med. 2016-3

[6]
Recent clinical advances in lung cancer management.

J Clin Oncol. 2014-2-24

[7]
Emerging gene mutation targets in lung cancer.

Clin Adv Hematol Oncol. 2015-12

[8]
A case of residual non-small cell lung cancer cells coexisting with newly developed small cell lung cancer cells in ascitic fluid after chemotherapy for non-small cell lung cancer.

Ann Lab Med. 2014-3

[9]
Perspectives in Lung Cancer--Third Asian-pacific Conference. 11-12 September 2009, Bangkok, Thailand.

IDrugs. 2009-11

[10]
Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.

Respir Investig. 2012-9

引用本文的文献

[1]
Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC).

Healthcare (Basel). 2025-7-25

[2]
Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients.

Front Oncol. 2025-7-24

[3]
Mediastinal staging of nonsmall cell lung cancer: what's new?

Breathe (Sheff). 2025-7-15

[4]
RPSLearner: A novel approach based on random projection and deep stacking learning for categorizing NSCLC.

bioRxiv. 2025-5-7

[5]
KIAA1429 promotes non-small-cell lung cancer cell proliferation through the TRERNA1/HOXA6 axis.

Sci Rep. 2025-7-10

[6]
Metabolic alterations driven by LDHA in CD8 + T cells promote immune evasion and therapy resistance in NSCLC.

Sci Rep. 2025-7-8

[7]
Accurate prediction of disease-free and overall survival in non-small cell lung cancer using patient-level multimodal weakly supervised learning.

NPJ Precis Oncol. 2025-6-19

[8]
Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer.

Acta Pharmacol Sin. 2025-6-6

[9]
Identification of a Biomarker Panel in Extracellular Vesicles Derived From Non-Small Cell Lung Cancer (NSCLC) Through Proteomic Analysis and Machine Learning.

J Extracell Vesicles. 2025-5

[10]
MDMX enhances radiosensitivity in lung adenocarcinoma and squamous cell carcinoma by inhibiting P53-mediated autophagy.

Cell Oncol (Dordr). 2025-5-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索